Pasireotide (Signifor®, Signifor LAR®): A Comprehensive Monograph on a Multireceptor-Targeted Somatostatin Analog

Executive Summary and Introduction

Overview

Pasireotide is a second-generation, multireceptor-targeted somatostatin analog (SSA) representing a significant evolution in the medical management of certain endocrine disorders.[1] Developed initially by Novartis and now part of the portfolio of Recordati Rare Diseases, Pasireotide is a synthetic, long-acting cyclic hexapeptide engineered to mimic the inhibitory actions of the natural hormone somatostatin.[2] It is commercially available under two distinct brand names corresponding to its formulation and route of administration: Signifor®, a solution for subcutaneous (SC) injection, and Signifor LAR®, a long-acting release (LAR) formulation for intramuscular (IM) injection.[6]

Primary Indications

Pasireotide holds orphan drug status and is approved for two primary indications. It is used for the treatment of adult patients with Cushing's disease, a condition of chronic hypercortisolism, for whom pituitary surgery is not a viable option or has not been curative.[6] Additionally, the long-acting formulation, Signifor LAR®, is approved for the treatment of acromegaly, a disorder of excessive growth hormone (GH) secretion, in adult patients who have demonstrated an inadequate response to surgery or for whom surgery is not an option.[6]

Core Mechanism and Clinical Distinction